Brought to you by 
Novartis licenses rights in emerging markets to GW Pharma's Sativex
05 May 2021
Executive Summary
Novartis Pharma AG has licensed exclusive marketing rights in Australia, New Zealand, Asia (excluding Japan, China, and Hong Kong), the Middle East (excluding Israel/Palestine, which is Neopharm Ltd.’s licensed area), and Africa to GW Pharmaceuticals PLC’s (cannabis therapeutics) Sativex (tetrahydrocannabinol/cannabidiol).
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Novartis licenses rights in emerging markets to GW Pharma's Sativex
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice